6/26/2025

The AMG GW&K Small/Mid Cap Core Fund returned -8.17% for the first quarter of 2025, compared with -7.50% for its benchmark, the Russell 2500 Index.

Source: SeekingAlpha

6/25/2025

Source: SeekingAlpha

6/25/2025

Sarah Karlin-Smith of Pink Sheet reported via X: “RFK says HHS about to launch one of the biggest campaigns in HHS history to encourage Americans to use wearable health devices (like CGMs). His vision is every American wearing “wearable” in 4 years.” Shares of companies in the continuous glucose monitoring space moved higher intraday, including Tandem Diabetes (TNDM), DexCom (DXCM), Insulet (PODD), Abbott (ABT) and Medtronic (MDT). Published first on TheFly – the ultimate source for real-time, m

Source: Yahoo

6/25/2025

The strategy and product exec said Tandem aims to give patients options and reach more people who haven’t yet used insulin pumps.

Source: Yahoo

6/25/2025

Tandem Diabetes Care delivered a first-quarter performance that exceeded Wall Street’s revenue expectations, with management attributing growth to stronger pump demand, expanding pharmacy channel access, and increased adoption of its new Tandem Mobi pump and Control-IQ+ algorithm. CEO John Sheridan highlighted that more than two-thirds of new U.S. customers converted from multiple daily injections, signaling success in reaching previously untapped users. The company also saw record international

Source: Yahoo

6/25/2025

The Victory RS Small Cap Growth Fund (Class A Shares, without sales charge) returned -16.29% for the three months ended March 31, 2025, underperforming the Russell 2000® Growth Index.

Source: SeekingAlpha

6/24/2025

Medtronic, Beta Bionics and Tandem Diabetes Care showcased planned patch pumps at the conference, while Senseonics shared updates on its implantable glucose sensors.

Source: Yahoo

6/23/2025

Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.

Source: Yahoo

6/23/2025

The early access programme for the integration has already commenced in the US.

Source: Yahoo

6/20/2025

SAN DIEGO, June 20, 2025--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025.

Source: Yahoo

6/20/2025

Tandem Diabetes Care, Inc. announced the Tandem t:slim X2?? insulin pump with Control-IQ+ automated insulin delivery technology now works with Abbott's FreeStyle Libre®? 3 Plus continuous glucose...

Source: Finnhub

6/20/2025

Tandem continues to build its technology ecosystem to expand choice and personalization for people living with diabetes...

Source: Finnhub

6/17/2025

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Deutsche Bank upgraded Cisco (CSCO) to Buy from Hold with a price target of $73, up from $65. The firm sees improved visibility towards “durable” mid-single-digit growth in upcoming years for Cisco, with tailwinds from artificial intelligence, a Campus portfolio refresh, more favorable near-term compet

Source: Yahoo

6/17/2025

While Tandem Diabetes Care, Inc. ( NASDAQ:TNDM ) might not have the largest market cap around , it saw a significant...

Source: Yahoo

6/17/2025

Abbott Laboratories (NYSE:ABT) is one of the best stocks to buy for beginners now. On June 10, Tandem Diabetes Care Inc. (NASDAQ:TNDM) announced a new agreement with Abbott to develop and commercialize integrated diabetes solutions. The collaboration will combine Abbott’s future dual glucose-ketone sensor with Tandem’s innovative insulin delivery systems, with the aim of providing […]

Source: Yahoo

6/16/2025

Investing.com -- Truist Securities launched coverage on four diabetes technology companies, saying there is a long-term growth potential for continuous glucose monitors (CGM) and insulin pumps amid rising adoption in both type 1 and type 2 diabetes patients.

Source: Yahoo

6/10/2025

Tandem Diabetes Care, Inc. announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin...

Source: Finnhub

6/10/2025

Presenter SpeechUnknown Executive Okay. Speaker 0 Well, good morning, everyone. I want to welcome President and CEO of Tandem Diabetes; and Susan Morrison, Senior Vice President -- Executive Vice...

Source: Finnhub

6/10/2025

What a brutal six months it’s been for Tandem Diabetes. The stock has dropped 39% and now trades at $20.61, rattling many shareholders. This may have investors wondering how to approach the situation.

Source: Yahoo

6/9/2025

Presenter SpeechMatthew Taylor So thanks a lot for joining us for the session here with Tandem Diabetes. We have Leigh Vosseller, the CFO; and Katie from Investor Relations. We're going to have

Source: Finnhub